RDO Pharm. Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2018
NCT03974685
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

RDO Pharm.

Active Ingredients

Drugs in Phase 3 Trials (1)

99mtc-3prgd2 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1